Abstract

Building on the success of the Lighthouse lab at Alderley Park, the Medicines Discovery Catapult are creating a £13M Infectious Diseases Research Facility due for completion summer 2022, incorporating 8,000 sq. ft. of state-of-the-art biosafety level 3 (BSL3) laboratories. Supported by UK government and regional funding, this new facility will be available for UK SMEs and academic innovators to accelerate their infectious diseases drug and vaccine discovery and will form part of the UK’s pandemic readiness infrastructure. The facility will house high end bioimaging, bioanalysis and high throughput screening capabilities for ACDP category 2, 3 and schedule 5 pathogens and will be supported by Medicines Discovery Catapult scientists experienced in anti-bacterial, anti-viral and vaccine discovery. The Medicines Discovery Catapult would be delighted to talk to anyone who might be interested in collaborating or working with us.